Citation: | ZHANG Ya, ZHANG Jinlin, ZHAO Shuqiang, YUAN Yaozuo, ZHANG Mei, FAN Xialei, WANG Yalou. Preparation of impurity C of doxycycline hyclate and its evaluation of in vitro antimicrobial activity and toxicity[J]. Journal of China Pharmaceutical University, 2016, 47(4): 463-468. DOI: 10.11665/j.issn.1000-5048.20160412 |
[1] |
Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-antimicrobial organ protective properties:possible mechanisms of action[J].Pharm Res,2011, 63:102-107.
|
[2] |
Soni MP,Mahajan MV,Dhumal RV,et al.Genotoxicity evaluation of asymmetric lipid polymer hybrid nanoparticles of doxycycline hydrochloride following intravenous administration[J].Drug Deliv Transl Res,2013, 3(5):421-427.
|
[3] |
Chanta C, Phloenchaiwanit P. Randomized controlled trial of azithromycin versus doxycycline or chloramphenicol for treatment of uncomplicated pediatric scrub typhus[J].J Med Assoc Thai,2015, 98(8):756-760.
|
[4] |
Ruan Y,Han Z,Han X.Report:Clinical curative effect of traditional Chinese medicine combined with doxycycline in the treatment of genital Chlamydia trachomatis and urea plasma urealyticum infections[J].Pak J Pharm Sci,2015, 28(4 Suppl):1555-1557.
|
[5] |
Wang YS,Zhou LM.Bioterrorism-related anthrax and antimicrobial therapy[J].Sichuan J Physiol Sci(四川生理科学杂志),2004;26(3):119-123.
|
[6] |
Chinese Pharmacopoeia Commission.Chinese Pharmacopoeia:part 2(中华人民共和国药典:二部)[S].Beijing:China Medical Science Press,2010:690-692.
|
[7] |
European Pharmacopoeia Commission.European Pharmacopoeia 8.0: volume Ⅱ[S].France:European Directorate for the Quality of Medicines & HealthCare,2014:2110.
|
[8] |
Fisher MW,Hillegas AB,Nazeeri PL.Susceptibility in vitro and in vivo of Pseudomonas pseudomallei to rifampin and tetracyclines[J].Appl Microbiol,1971,22(1):13-16.
|
[9] |
Bryant JE,Brown MP,Gronwall RR,et al.Study of intragastric administration of doxycycline:pharmacokinetics including body fluid,endometrial and minimum inhibitory concentrations[J].Equine Veterin J,2000, 32(3):233-238.
|
[10] |
Li WM,Bao YY,Zhou QX.Degradation pathways and main degradation products of tetracycline antibiotics:research progress[J].Chin J Applied Ecol(应用生态学报),2012, 23(8):2300-2308.
|
[1] | LI Zhenming, HUO Meirong, DENG Qidan, CHEN Dengjun, SUN Hongzhang. In vitro evaluation of saxagliptin and metformin hydrochloride sustained-release tablets[J]. Journal of China Pharmaceutical University, 2021, 52(5): 541-546. DOI: 10.11665/j.issn.1000-5048.20210505 |
[2] | ZHANG Jinlin, YUAN Yaozuo, ZHANG Ya, ZHAO Shuqiang, ZHAO Xun, ZHANG Mei. Consistency evaluation of domestic generic rifampicin capsules and reference drug in vitro[J]. Journal of China Pharmaceutical University, 2018, 49(5): 603-609. DOI: 10.11665/j.issn.1000-5048.20180513 |
[3] | Study on Optimize the Preparation and Formulation of Nimodipine-Containing Nanoliposome[J]. Journal of China Pharmaceutical University, 2003, (1): 27-30. |
[4] | Distribution of Nimodipine Microemulsion in Mice In vivo and Evaluation on Its Targeting Performance[J]. Journal of China Pharmaceutical University, 2002, (4): 31-34. |
[5] | Study on Transdermal Therapeutic System for Nimodipine[J]. Journal of China Pharmaceutical University, 2000, (5): 28-31. |
[6] | Development of Nimodipine Sustained Release Capsules[J]. Journal of China Pharmaceutical University, 1999, (5): 346-349. |
[7] | The Factors Influencing Nimodipine Release from Hydroxypropyl Methylcellulose Matrix Tablet[J]. Journal of China Pharmaceutical University, 1998, (6): 418-421. |
[8] | Improved Process of Nimodipine[J]. Journal of China Pharmaceutical University, 1998, (3): 82-83. |
[9] | Study on Penetration Enhancers for Nimodipine[J]. Journal of China Pharmaceutical University, 1994, (3): 149-152. |
[10] | CORRELATION BETWEEN THE ABSORPTION IN VIVO AND THE RELEASE IN VITRO OF TWO CONTROLLED-RELEASE TABLETS OF AMINOPHYLLINE[J]. Journal of China Pharmaceutical University, 1986, (1): 18-23. |